The inspection of Biocon's Bengaluru facility was triggered by a New Drug Application submitted by the company's insulin API customer
Shares of Biocon fell 2.71 percent in early trade on March 7 after receiving six observations from the US Food and Drug Administration (FDA) on inspection of the company's Bengaluru facility.
The FDA issued six observations in Form 483 after pre-approval inspection of Biocon's insulin drug substance manufacturing facility in Bengaluru.
The inspection took place between February 25 and March 5, the company said.
The inspection was triggered by a New Drug Application submitted by the company's insulin API customer.
At 0921 hours, Biocon was quoting at Rs 615.5 on the BSE, down 1.59 percent.
To get profitable financial guidance, give one missed call on 9644405056. We offer 2 days free trial. Our packages are affordable. Click here to visit our website : Stock Option Market Tips
No comments:
Post a Comment